| Bioactivity | Pantoprazole sodium (BY10232 sodium) is an orally active and potent proton pump inhibitor (PPI)[1]. Pantoprazole sodium, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole sodium improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole sodium significantly increased tumor growth delay combined with Doxorubicin (HY-15142)[3][4]. |
| Invitro | Pantoprazole sodium (BY1023 sodium; 1-10000 μM) leads to concentration-dependent increases in endosomal pH in EMT-6 and MCF7 cells[1].Pantoprazole sodium can block exosome release. Pantoprazole sodium inhibits the activity of V-H+-ATPase and impaires the ability of tumour cells (melanomas, adenocarcinomas, and lymphoma cell lines) to acidify the extracellular medium[2] |
| Name | Pantoprazole sodium |
| CAS | 138786-67-1 |
| Formula | C16H14F2N3NaO4S |
| Molar Mass | 405.35 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |
Pantoprazole sodium
CAS: 138786-67-1 F: C16H14F2N3NaO4S W: 405.35
Pantoprazole sodium (BY10232 sodium) is an orally active and potent proton pump inhibitor (PPI). Pantoprazole sodium, a
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.